NASDAQ:SMMT
Summit Therapeutics plc Stock News
$8.69
-2.24 (-20.47%)
At Close: May 31, 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 992
Biotech Stock Volatile After Upbeat Trial data
10:19am, Friday, 31'st May 2024
The shares of Summit Therapeutics Inc (NASDAQ:SMMT) appear to be headed for a minor correction after yesterday's skyrocket.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Thursday, 30'th May 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Thursday, 30'th May 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
04:29pm, Thursday, 30'th May 2024
Shares of Summit Therapeutics Inc. SMMT, +272.06% jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stag
Summit Therapeutics cancer therapy succeeds in late-stage China study
03:39pm, Thursday, 30'th May 2024
Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met
Why Summit Therapeutics Stock Is Sinking Today
12:13pm, Tuesday, 28'th May 2024
Summit Therapeutics' stock is falling sharply for the second consecutive trading day. The sell-off began after the company revealed disappointing late-state data for its lead pipeline candidate.
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
01:30pm, Wednesday, 08'th May 2024
NPMA decision on whether to approve Summit Therapeutics Inc.'s ivonescimab for the treatment of patients with EGFR-mutant metastatic non-squamous NSCLC following TKI progression is expected in Q2 of 2
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
11:02am, Monday, 06'th May 2024
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
10:00pm, Wednesday, 01'st May 2024
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Boa
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
07:00am, Wednesday, 01'st May 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
04:30pm, Wednesday, 24'th Apr 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
04:30pm, Thursday, 11'th Apr 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of D
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
07:00am, Wednesday, 10'th Apr 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targ